Pharmacological treatment of asthma today: Table 1
Authors:
- D.T. SchmidtDSD.T. Schmidt
Open Access
- 1 January 2001
- journal article
- review article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 18 (34 suppl) , 34s-40s
Abstract
The current concept of asthma therapy is based on a stepwise approach, depending on disease severity, and the aim is to reduce the symptoms that result from airway obstruction and inflammation, to prevent exacerbations and to maintain normal lung function.β2‐Adrenoceptor agonists and glucocorticoids are at present the most effective drugs for the treatment of airway obstruction and inflammation, with theophylline, leukotriene receptor antagonists and anticholinergics as second- or third-line therapy. There are, to date, no additional or newly developed drugs available that add substantially to the current strategies or even replace β2‐adrenoceptor agonists or glucocorticoids. New approaches in asthma therapy recommend drug combinations of inhaled steroids, primarily with long-acting β2‐adrenoceptor agonists, based on their improved efficacy and the potential for a steroid-sparing effect.Although existing drug entities are able to control the vast majority of patients with mild and moderate asthma, patients' (and doctors') adherence to guidelines and treatment strategies falls well short of the desired standards.Treatment choices, however, differ between countries and should take into account convenience to the patient and the occurrence of side-effects. Additionally, the cost of therapy and reimbursement policies also influences therapeutic strategies.Keywords
This publication has 35 references indexed in Scilit:
- Antimuscarinic treatment for lung diseases: From research to clinical practiceLife Sciences, 2001
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) studyEuropean Respiratory Journal, 2000
- Low-Dose Inhaled Corticosteroids and the Prevention of Death from AsthmaNew England Journal of Medicine, 2000
- A Long-term Study of the Antiinflammatory Effect of Low-dose Budesonide Plus Formoterol versus High-dose Budesonide in AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Safety of Inhaled and Intranasal CorticosteroidsDrug Safety, 2000
- Efficacy and Safety of Inhaled Corticosteroids: New DevelopmentsAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Effect of Inhaled Formoterol and Budesonide on Exacerbations of AsthmaNew England Journal of Medicine, 1997
- Synthetic Glucocorticoids That Dissociate Transactivation and AP-1 Transrepression Exhibit Antiinflammatory Activity in VivoMolecular Endocrinology, 1997
- Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamineJournal of Allergy and Clinical Immunology, 1987